Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PHILIP C HALVERSON

Allopathic & Osteopathic Physicians Allergy & Immunology Clinical & Laboratory Immunology

NPI
1083674501
CMS profile
3950
Location
MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,338.65

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,089.18 4
Food and Beverage $249.47 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $1,338.65 5

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PHILIP C HALVERSON

NPI 1083674501 · CMS profile ID 3950

Allopathic & Osteopathic Physicians / Allergy & Immunology / Clinical & Laboratory Immunology

MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083674501?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PHILIP C HALVERSON, NPI 1083674501, CMS profile ID 3950. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083674501?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PHILIP C HALVERSON, NPI 1083674501, CMS profile ID 3950. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083674501?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PHILIP C HALVERSON, NPI 1083674501, CMS profile ID 3950, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1083674501?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $1,338.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $106.8003/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672136219 CMS
PFIZER INC. $241.5001/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672133807 CMS
PFIZER INC. $247.4701/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672198693 CMS
PFIZER INC. $249.4701/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672246487 CMS
PFIZER INC. $493.4101/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672254279 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,338.65 5
PY2021 $18.58 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Principal investigator $1,231.40 1
PY2019 Recipient $1,971.95 11
PY2019 Principal investigator $81,935.37 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

60 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $257.69 12/25/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671670639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,919.34 12/19/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639733811
Principal investigator 1 PFIZER INC. $1,411.94 12/10/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671671269
Principal investigator 1 PFIZER INC. $1,411.94 11/23/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671672657
Principal investigator 1 PFIZER INC. $998.69 11/05/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671673149
Principal investigator 1 PFIZER INC. $1,588.88 11/02/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671674009
Principal investigator 1 PFIZER INC. $1,511.69 10/25/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671673229
Principal investigator 1 PFIZER INC. $5,679.69 10/08/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671675219
Principal investigator 1 SANOFI US SERVICES INC. $1,073.00 10/01/2019 Non-covered Recipient Entity
Clinical Research Inst Inc
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial No dispute reported 06/30/2026 691614815
Principal investigator 1 PFIZER INC. $1,511.69 09/04/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671668917
Principal investigator 1 PFIZER INC. $1,511.69 08/07/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671673979
Principal investigator 1 GlaxoSmithKline, LLC. $3,919.46 07/26/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669962111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.16 07/16/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639733803
Principal investigator 1 PFIZER INC. $3,423.57 07/10/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671677481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $200.27 07/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733799
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12.60 07/02/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733801
Principal investigator 1 PFIZER INC. $3,621.88 06/25/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671645117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $904.95 06/19/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,196.16 05/29/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733781
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 05/21/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669962109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $482.64 05/15/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733779
Principal investigator 1 PFIZER INC. $4,500.00 05/09/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 671625177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $324.87 05/08/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $192.78 05/08/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,064.92 05/08/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $138.10 05/08/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733777
Recipient Regeneron Pharmaceuticals, Inc. $425.26 05/08/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750775
Recipient Regeneron Pharmaceuticals, Inc. $26.15 05/08/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750777
Recipient Regeneron Pharmaceuticals, Inc. $127.02 05/08/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750779
Recipient Regeneron Pharmaceuticals, Inc. $50.00 05/08/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750781
Recipient Regeneron Pharmaceuticals, Inc. $19.96 05/08/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750783
Recipient Regeneron Pharmaceuticals, Inc. $59.75 05/08/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750785
Recipient Regeneron Pharmaceuticals, Inc. $34.80 05/02/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750769
Recipient Regeneron Pharmaceuticals, Inc. $20.62 05/02/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750771
Recipient Regeneron Pharmaceuticals, Inc. $84.00 05/02/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750773
Principal investigator 1 SANOFI US SERVICES INC. $1,034.00 05/02/2019 Non-covered Recipient Entity
Allergy Asthma Specilaist,PA Clinical Research Institute,Inc
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial No dispute reported 06/30/2026 691580471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $422.31 04/17/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733793
Recipient Regeneron Pharmaceuticals, Inc. $191.80 04/08/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750767
Principal investigator 1 SANOFI US SERVICES INC. $533.00 04/02/2019 Non-covered Recipient Entity
Allergy Asthma Specilaist,PA Clinical Research Institute,Inc
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial No dispute reported 06/30/2026 691576355
Principal investigator 1 PFIZER INC. $24.00 03/31/2019 Non-covered Recipient Entity
Clinical Research Institute
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671645121
Principal investigator 1 PFIZER INC. $96.00 03/31/2019 Non-covered Recipient Entity
Clinical Research Institute
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671645199
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 03/28/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639733785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,800.00 03/28/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639733787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,458.02 03/27/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE INC
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients 6 Months to 18 Years of Age With Atopic Dermatitis No dispute reported 06/30/2026 639733783
Principal investigator 1 GlaxoSmithKline, LLC. $356.40 03/18/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
AN OPEN-LABEL STUDY TO EVALUATE CORRECT USE AND EASE OF USE OF THE ELL No dispute reported 06/30/2026 669972059
Principal investigator 1 SANOFI US SERVICES INC. $600.00 03/01/2019 Non-covered Recipient Entity
Clinical Research Institute
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial No dispute reported 06/30/2026 691548001
Principal investigator 1 PFIZER INC. $24.00 02/28/2019 Non-covered Recipient Entity
Clinical Research Institute
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671645119
Principal investigator 1 PFIZER INC. $96.00 02/28/2019 Non-covered Recipient Entity
Clinical Research Institute
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671645201
Principal investigator 1 PFIZER INC. $577.08 02/22/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671624967
Principal investigator 1 PFIZER INC. $49.96 02/22/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671624993
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,000.00 02/18/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD OF CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 640713809
Recipient Regeneron Pharmaceuticals, Inc. $932.59 02/18/2019 Covered Recipient Physician A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis No dispute reported 06/30/2026 639750765
Principal investigator 1 SANOFI US SERVICES INC. $1,021.00 02/04/2019 Non-covered Recipient Entity
Clinical Research Institute
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial No dispute reported 06/30/2026 691549635
Principal investigator 1 SANOFI US SERVICES INC. $636.00 02/04/2019 Non-covered Recipient Entity
Clinical Research Institute
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial No dispute reported 06/30/2026 691549640
Principal investigator 1 PFIZER INC. $4,500.00 02/02/2019 Non-covered Recipient Entity
Clinical Research Institute Inc
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671625225
Principal investigator 1 PFIZER INC. $70.00 02/01/2019 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671645123
Principal investigator 1 PFIZER INC. $96.00 01/31/2019 Non-covered Recipient Entity
Clinical Research Institute
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671645125
Principal investigator 1 PFIZER INC. $24.00 01/31/2019 Non-covered Recipient Entity
Clinical Research Institute
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 671645203
Principal investigator 1 SANOFI US SERVICES INC. $180.00 01/09/2019 Non-covered Recipient Entity
Clinical Research Inst Inc
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study No dispute reported 06/30/2026 691543499
Principal investigator 1 SANOFI US SERVICES INC. $3,559.00 01/02/2019 Non-covered Recipient Entity
Clinical Research Institute
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial No dispute reported 06/30/2026 691549090